In conclusion, the case-control study explored the association of MYBL2 polymorphisms (rs285162, rs285207, and rs2070235) with childhood ALL risk and firstly demonstrated that the rs285207 A>C in MYBL2 gene decreased the risk of childhood ALL and might influence the transcription of MYBL2 via altering IKZF1 binding, which suggested that MYBL2 polymorphism might serve as a biomarker for ALL susceptibility. This evidence concerns the gene MYBL2 and acute lymphoblastic leukemia.